Johnson & Johnson $JNJ Stock Holdings Lifted by Provenance Wealth Advisors LLC

Key Points

• Provenance Wealth Advisors increased its Johnson & Johnson stake 214.5% in the third quarter, to 15,890 shares worth about $4.2 million. Institutional investors collectively own 69.55% of the stock.
• J&J reported quarterly EPS of $2.59, beating the $2.53 consensus, while revenue rose 5.9% year over year to $25.4 billion. The company forecast fiscal 2026 EPS of $11.05–$11.15.
• Analysts’ consensus rating is Moderate Buy, with a $275.92 average price target. J&J also declared a $1.34 quarterly dividend, equivalent to a 1.9% yield at the price cited.

Provenance Wealth Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 214.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 15,890 shares of the company's stock after purchasing an additional 10,838 shares during the period. Provenance Wealth Advisors LLC's holdings in Johnson & Johnson were worth $4,207,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also modified their holdings of the company. Jupiter Topco LLC purchased a new position in Johnson & Johnson during the second quarter worth about $1,967,399,000. Corient Private Wealth LP raised its stake in shares of Johnson & Johnson by 127.3% in the 2nd quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock valued at $1,539,292,000 after acquiring an additional 3,393,981 shares during the period. Wellington Management Group LLP raised its stake in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after acquiring an additional 2,513,321 shares during the period. Amundi lifted its holdings in shares of Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after acquiring an additional 2,001,139 shares during the last quarter. Finally, SEB Asset Management AB acquired a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $314,468,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer Taubert sold 15,000 shares of the company's stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares of the company's stock, valued at approximately $51,210,615.36. This represents a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 33,597 shares of the firm's stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on JNJ shares. UBS Group set a $270.00 target price on shares of Johnson & Johnson in a report on Wednesday, October 14th. TD Cowen restated a "buy" rating on shares of Johnson & Johnson in a research note on Tuesday, October 20th. Freedom Capital upgraded Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research note on Thursday, July 16th. Wall Street Zen downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Finally, Sanford C. Bernstein set a $270.00 target price on Johnson & Johnson in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.92.

Johnson & Johnson Trading Up 3.9%

NYSE:JNJ opened at $276.62 on Thursday. Johnson & Johnson has a 12-month low of $185.12 and a 12-month high of $282.02. The firm has a market cap of $665.92 billion, a PE ratio of 41.91, a price-to-earnings-growth ratio of 2.63 and a beta of 0.22. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average price of $265.67 and a 200 day moving average price of $247.74.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter last year, the company earned $2.80 EPS. Johnson & Johnson's revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson's dividend payout ratio (DPR) is presently 81.21%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Wall Street analysts remain moderately bullish on J&J’s prospects, according to a review of analyst views. Read article
• Neutral Sentiment: State Street’s Health Care SPDR added J&J shares as part of a $175.3 million purchase that increased all 60 of the fund’s holdings. This indicates fund buying, but the report does not specify J&J’s allocation or suggest a company-specific investment view. Read article
• Neutral Sentiment: Smith+Nephew cut its outlook and confirmed failed merger discussions with J&J’s orthopedics unit. The talks’ failure removes a potential transaction, but the report does not detail any direct financial impact on J&J. Read article
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of J&J investors. The announcement could create negative legal overhang, although it does not provide details about the claims or establish wrongdoing. Read article

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.